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To the Editor: We read with interest the article by 
Furuya-Kanamori et al. on the proportion of influenza vi-
rus infections that are asymptomatic or subclinical (1), and 
we are troubled by a series of fundamental flaws and er-
rors. We were concerned that the authors presented pooled 
estimates of the asymptomatic fraction, given the massive 
heterogeneity in estimates (Ι2 values of 97%–98% in Table 
1). It is not considered good practice to present pooled es-
timates in instances of massive heterogeneity (2). We were 
very surprised that the authors included volunteer challenge 
studies because it is well known that the severity of these 
infections can be modulated by the route of administration 
and possibly the infectious dose. We also were surprised 
that human infections with avian influenza viruses were in-
cluded because the epidemiology of these infections differs 
markedly from that of human influenza viruses. These stud-
ies were mistakenly labeled as studies of pandemic influen-
za in online Technical Appendix 1 Table 1 (https://wwwnc.
cdc.gov/EID/article/22/6/15-1080-Techapp1.pdf). When 
reviewing serologic studies, the authors did not define a 
specific antibody titer threshold but relied on the choices 
made in individual studies; studies that inferred influenza 
virus infections based on low postepidemic hemagglutina-
tion-inhibition titers, such as 10 or 20, may lack specificity 
because some persons could have preexisting antibodies 
(3). Measurement error can also be a concern. The authors 
probably should have excluded such studies.
In another systematic review of the asymptomatic frac-
tion of influenza virus infections (4), we found that study de-
signs could explain a great deal of heterogeneity in the asymp-
tomatic fraction in studies such as outbreak investigations 
that used molecular testing to confirm influenza virus infec-
tions rather than serologic studies that used antibody titer 
measurements to indicate infections. Asymptomatic frac-
tions were higher in general, and much more heterogeneous, 
in studies that followed the latter approach.
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LETTERS
In Response: We thank Leung and Cowling (1) for 
taking time to comment on our article (2). One problem 
with the random effects model is the rapid decline in per-
formance of the model as the heterogeneity within stud-
ies increases. Extensive heterogeneity for asymptomatic 
(Ι2 = 97%; Τ2 = 0.31) and subclinical (Ι2 = 97%; Τ2 = 0.45) 
infection was identified. However, the model selected 
to pool the prevalence estimates—inverse variance 
heterogeneity—maintains its coverage at the nominal level, 
even when large heterogeneity is present (3).
Regarding inclusion criteria, we elected to review all 
publications detailing asymptomatic influenza prevalence in 
humans, as is made clear from the original article’s title on-
ward. This method included experimental studies, as well as 
newly emerging zoonotic strains. We note further that the 2 
experimental studies in our review had subclinical influenza 
infection levels within the range identified in the pooled es-
timate of the metaanalysis (43.4%, 95% CI 25.4%–61.8%). 
Also, because antibody titers can vary drastically with tech-
nique used and between laboratories, we used the antibody 
titer threshold defined by each individual study.
The results/conclusions from the study published 
by Leung et al. (4) cannot be compared with those re-
ported in our meta-analysis (2) for 2 important reasons. 
First, the case definition for asymptomatic was different; 
Leung et al. grouped patients without signs and symp-
toms (asymptomatic in our metaanalysis) with patients 
that did not fulfill the criteria of influenza-like illness 
(subclinical in our meta-analysis). We explained in our 
article why pooling asymptomatic and subclinical cases 
is inappropriate and likely to provide spurious results. 
As an example of how the case definition can affect the 
results, Pascalis et al. found that in the same group of 
patients, 30.6% had subclinical infection (not fulfilling 
criteria for influenza-like illness) but only 1.6% had no 
symptoms at all (5). Second, the number of studies in-
cluded in the 2 meta-analyses was different: our compre-
hensive review comprised 55 studies, whereas Leung et 
al. included a subset of only 30 studies pertaining spe-
cifically to seasonal influenza. The different studies in-
cluded and different meta-analytical methods unsurpris-
ingly yielded different outcomes.
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To the Editor: The article by Virk et al. (1) highlighted 
that a person can acquire Mycobacterium lepromatosis infec-
tion without exposure to a person infected with leprosy or to 
known vectors during short stays (2 trips of 7 days each over 
3 calendar years) in Mexico. The authors then concluded that 
M. lepromatosis lepromatous leprosy is a travel-related haz-
ard for travelers to Mexico or other disease-endemic areas. 
We note that the exact source of acquiring the M. lepromato-
sis infection by the patient in this study was entirely uncer-
tain, and experimental evidence was not enough to prove M. 
lepromatosis to be a travel-related hazard.
In contrast, Jessamine et al. (2) reported M. lepromato-
sis infection and leprosy-like illness in a patient in Canada 
who had no history of contact or travel to leprosy-endemic 
areas. Jessamine et al. indicated that transmission dynamics 
of M. lepromatosis infection is complex, and undiscovered 
mechanisms or unknown reservoir interactions may exist 
in such areas of nonendemic regions. Previous studies have 
also reported the roles of subclinical cases and environmen-
tal reservoirs in the transmission of leprosy (3,4). However, 
Virk et al. have not disentangled other possible sources 
(existence of unrecognized subclinical cases, contact with 
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